Avastin (Intravitreal Bevacizumab) (Genentech Inc.) for treatment of choroidal neovascularization secondary to pathological myopia
Pathological myopia refers to an abnormal elongation of the eye and is associated with extreme nearsightedness. It can result in a progressive, severe loss of vision and is requently related to the development of choroidal neovascularization (CNV). Pathological myopia has an incidence of approximately 2% in the general U.S. population and is the seventh leading cause of legal blindness. It occurs most often in those of Chinese, Japanese, Middle Eastern, or Jewish descent; and it is more common in women than men. Pathological myopia is the primary cause of CNV in individuals younger than 50 years of age. Nearly 10% of eyes with pathological myopia develop CNV. If left untreated, the visual prognosis of CNV secondary to pathological myopia is poor, and a high proportion of patients develop rapid and potentially irreversible vision loss.
- Injections
- Antibodies, Monoclonal
- Choroidal Neovascularization
- Myopia, Degenerative